Eureka Therapeutics is a preclinical-stage company developing innovative T cell immunotherapies for the treatment of solid tumors. Our first clinical program for the treatment of liver cancer is projected to enter the clinic in 2017.
Renowned physician-scientist, David A. Scheinberg, MD, PhD, to join Scientific Advisory Board of Eureka Therapeutics
Our pipeline encompasses T cell therapies targeting well-studied cancer specific antigens, e.g. testis antigens, mutated oncogenes, viral antigens. Our lead program for liver cancer, ET1402, is expected to enter Phase I in 2017.
Collaborations are a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.